Intensity Therapeutics doses first patient in Phase 3 sarcoma trial; cash $6.3M into Q1 2025

INTENSITY THERAPEUTICS, INC.

2024-Q2 EPS reported -$0.70

First patient dosed in Phase 3 INVINCIBLE-3 study of INT230-6 vs SOC in soft tissue sarcoma; plans 333 patients.
Collaboration with SAKK for Phase 2 INVINCIBLE-4 study in early-stage triple-negative breast cancer; start Q3 2024.
Net loss $5.0M in Q2 2024 vs $3.7M in Q2 2023; R&D expenses $3.6M (up from $0.9M).
Cash, cash equivalents and marketable debt securities $6.3M as of June 30, 2024.
Appointed Thomas Dubin, J.D., MPH to board of directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.